---

Method development and validation for simultaneous estimation of amlodipine besylate and enalapril maleate in solid dosage form

Full Text PDF Share on Facebook Share on Twitter

---

Original Article

Author Details : Manisha Masih*

Volume : 8, Issue : 3, Year : 2021

Article Page : 129-133

https://doi.org/10.18231/j.ijpca.2021.025

Suggest article by email

Get Permission

Abstract

A rapid, sensitive, specific, accurate and precise high pressure liquid chromatographic method (HPLC) method involving UV detection has been developed for the determination and quantification of Amlodipine Besylate and Enalapril maleate in bulk and combined dosage form. The determination was carried out on a Phenomenex C18 column (Dimention : 250 x 4.6 mm, 5 ?m). The sample was analysed using filtered and degassed mixture of methanol : 0.1N HCl (1:1) as mobile phase at a flow rate of 1ml/min and effluent was monitored at 218nm. The retention time for Amlodipine besylate was 7.6 min and for Enalapril maleate 3.2 min. Amlodipine besylate and Enalapril maleate showed a linear response in the concentration range of 10-50?g/ml. The correlation co-efficient ('r' value) for Amlodipine besylate and Enalapril maleate was 0.9992 and 0.9994, respectively. The method was validated in terms of linearity, precision, accuracy, specificity, robustness and solution stability. The proposed method can be used for routine analysis of Amlodipine Besylate and Enalapril maleate in bulk and combined dosage form

Keywords: Amlodipine besylate, Enalapril maleate, Method development, Validation, HPLC

How to cite : Masih M, Method development and validation for simultaneous estimation of amlodipine besylate and enalapril maleate in solid dosage form. Int J Pharm Chem Anal 2021;8(3):129-133

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.